| Investment points Company Marketing Adjustment | | | | seriously affected the later development, the |
| basically completed. Benefit from the medical reform, | | | | company controlled the second half of 2008 |
| its varieties of potential drugs, while rabies vaccine will | | | | shipments and inventory liquidation channels. To the |
| be a new profit growth point, future performance is | | | | original channel of the third quarter of 2009, stocks |
| expected to significantly reverse. | | | | of basic clean-up completed, the sales to track. |
| Wanglaoji expected to maintain 25% growth. Canton | | | | Quarterly Bulletin last year, showing sales revenue |
| Medicine Future to look forward to the company. | | | | and net profit into positive growth, which main |
| Moreover, the integrated system is expected to | | | | business net profit rose 75%. Show the company |
| remain drug. | | | | has begun selling becomes normal track, started to |
| Forecasting firm 2009 -2011 Earnings per share were | | | | improve management quality. |
| 0.22 yuan, 0.44 yuan and 0.59 yuan for the first time | | | | Company owns, including Chen Li Chi, Jing Xiu Tang, |
| to "strongly recommended" rating. | | | | Zhi-Lin Pan Gaoshou and mining and other century-old, |
| Risk Note: Performance may reverse the extent and | | | | with Xiaoke Pill, Wujibaifeng Pills, Huatuozaizao pill, Po |
| persistence of lower than expected; Guangzhou | | | | Chai Pills, ointment mixing Loquat well-known brand |
| Pharmaceutical system integration uncertainty. | | | | Chinese medicine preparation. Huatuozaizao pill which |
| Guangzhou Pharmaceutical [11.575.47%] (600 332) for | | | | Xiaoke Pill and essential drugs for the exclusive |
| the large state in southern China Pharmaceutical | | | | varieties, annual sales income of 5 billion yuan |
| companies , Ltd. Traditional Chinese medicine | | | | respectively, and 1.5 billion yuan. We believe that the |
| Materials, manufacturing and proprietary Chinese | | | | company is much larger than the potential benefit of |
| medicines Drugs Wholesale, retail and import and | | | | medical reform other small and medium sized |
| export trade. Quarterly Bulletin 2009, showing the | | | | pharmaceutical company. Which is expected to |
| three main business income of 2.9 billion, net profit of | | | | Xiaoke pill sales in 2010 expected to grow more than |
| 153 million yuan, net profit excluding non-recurring | | | | 30%, sales revenue is expected to reach about 650 |
| gains and losses rose 75%. Since the upstream | | | | million yuan. Huatuozaizao pill will restore rapid growth. |
| element of raw materials prices fell 2.5 percent gross | | | | The constellation of Pharmaceutical drug sales in 2010 |
| margin, but the expense ratio decreased 3.3% during | | | | returned to normal, fade out and stop drink |
| the period in which Sell Costs down 15%. | | | | beverage industry promotion costs, the company will |
| Adjusted results are expected to reverse marketing | | | | be profitable. Pan Gaoshou medicine after two years |
| 2007, the company has taken aggressive sales | | | | of adjusted sales in 2010 will go on the right track, |
| strategy, the company to increase sales and channel | | | | you may return to 2006 sales levels and profitability. |
| performance using a large number of Yahuo way, | | | | |